Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00514449
Status:
COMPLETED
Last Update Posted:
2018-06-14
First Post:
2007-08-08
Brief Title:
Systematic Evaluation of Antiviral Medication in Schizophrenia
Sponsor:
Konasale Prasad
Organization:
University of Pittsburgh
Study Overview
Official Title:
A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SEAMS
Brief Summary:
The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus type 1 HSV 1 a virus that causes commonly occurring and recurrent cold sores
Detailed Description:
The main objective of the study is to evaluate the efficacy of add-on treatment of Valacyclovir VAV an antiviral medication in the treatment of early course schizophreniaschizoaffective disorder patients Our main hypothesis is that the VAV add-on treatment will improve positive negative and cognitive symptoms in herpes simplex virus HSV positive schizophrenia or schizoaffective disorder patients We hypothesize that the grey matter reductions in specific brain regions such as prefrontal regions will improve in patients on VAV antipsychotic compared to those on placebo antipsychotic and the improvements in positive negative and cognitive symptoms will be correlated with the grey matter changes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None